S
Saúl Campos-Gómez
Researcher at Universidad Autónoma del Estado de México
Publications - 31
Citations - 1327
Saúl Campos-Gómez is an academic researcher from Universidad Autónoma del Estado de México. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 7, co-authored 25 publications receiving 794 citations. Previous affiliations of Saúl Campos-Gómez include Monterrey Institute of Technology and Higher Education.
Papers
More filters
Journal ArticleDOI
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Seock-Ah Im,Yen-Shen Lu,Aditya Bardia,Nadia Harbeck,Marco Colleoni,Fabio Franke,Louis W.C. Chow,Joohyuk Sohn,Keun-Seok Lee,Saúl Campos-Gómez,Rafael Villanueva-Vazquez,Kyung Hae Jung,Arunava Chakravartty,Gareth Hughes,Ioannis Gounaris,Karen Rodriguez-Lorenc,Tetiana Taran,Sara A. Hurvitz,Debu Tripathy +18 more
TL;DR: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine Therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer.
Journal ArticleDOI
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy,Seock-Ah Im,Marco Colleoni,Fabio Franke,Aditya Bardia,Nadia Harbeck,Sara A. Hurvitz,Louis W.C. Chow,Joohyuk Sohn,Keun Seok Lee,Saúl Campos-Gómez,Rafael Villanueva Vazquez,Kyung Hae Jung,K Govind Babu,Paul Wheatley-Price,Michelino De Laurentiis,Young-Hyuck Im,Sherko Kuemmel,Nagi S. El-Saghir,Mei Ching Liu,Gary Carlson,Gareth Hughes,I Diaz-Padilla,C. Germa,Samit Hirawat,Yen-Shen Lu +25 more
TL;DR: In this paper, ribociclib plus endocrine therapy showed improved progression-free survival compared with letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-positive, HER2-negative, advanced breast cancer.
Proceedings ArticleDOI
Abstract GS2-05: First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial
Debu Tripathy,Jung Ho Sohn,S-A Im,Marco Colleoni,Fabio Franke,Aditya Bardia,Nadia Harbeck,S Hurvitz,Lwc Chow,KS Lee,Saúl Campos-Gómez,R. Villanueva Vázquez,Kyung Hwa Jung,Gary Carlson,Gareth Hughes,I Diaz-Padilla,C. Germa,S Hirawat,Y-S Lu +18 more
TL;DR: The first dedicated trial investigating a CDK4/6 inhibitor in pre- and peri-menopausal women with HR+, HER2– ABC demonstrated that addition of ribociclib to first-line ET (tamoxifen/NSAI + goserelin) significantly prolonged PFS and had a manageable safety profile.
Proceedings ArticleDOI
Abstract PD2-04: Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib
Debu Tripathy,Seock-Ah Im,Marco Colleoni,Fabio Franke,Aditya Bardia,Nadia Harbeck,Sara A. Hurvitz,Louis W.C. Chow,Joohyuk Sohn,Keun Seok Lee,Saúl Campos-Gómez,Rafael Villanueva Vazquez,Kyung Hae Jung,K Govind Babu,Paul Wheatley-Price,Michelino De Laurentiis,Young-Hyuck Im,Sherko Kümmel,Nagi S. El-Saghir,Mei-Ching Liu,Sharonjeet Kaur,Claudia Gasch,Craig Wang,Yongyu Wang,Arunava Chakravartty,Yen-Shen Lu +25 more
TL;DR: With an extended follow-up of more than 4 years, RIB + ET continued to demonstrate a clinically relevant OS benefit compared with ET alone in pre- or perimenopausal patients, and a similar benefit with RIB was observed for PFS2, time to CT, and CT-free survival.
Journal ArticleDOI
Guía de Práctica Clínica Nacional para el manejo del Cáncer de Pulmón de células no pequeñas en estadios tempranos, localmente avanzados y metastásicos
Feliciano Barrón-Barrón,Enrique Guzmán-de Alba,Jorge Arturo Alatorre-Alexander,Fernando Aldaco-Sarvide,Yolanda Bautista-Aragón,Mónica Blake-Cerda,Yazmín Carolina Blanco-Vázquez,Saúl Campos-Gómez,José Francisco Corona-Cruz,Marco Antonio Iñiguez-García,Francisco Javier Lozano-Ruiz,Federico Maldonado-Magos,Dolores de la Mata-Moya,Luis Manuel Martínez-Barrera,Rubí Ramos-Prudencio,Jerónimo Rafael Rodríguez-Cid,Samuel Rivera-Rivera,Raúl Rogelio Trejo-Rosales,Marco Rodrigo Aguilar-Ortíz,Horacio Astudillo-de la Vega,Luis Javier Barajas-Figueroa,Nimbe Barroso-Quiroga,Andrés Blanco-Salazar,Graciano Castillo-Ortega,Luis Manuel Domínguez-Parra,María Isabel Enríquez-Aceves,Armando Fernández-Orozco,Marco Antonio Figueroa-Morales,León Green-Schneewiss,Jorge Alejandro González-Garay,Rogelio González Ramírez-Benfield,Alberto Guadarrama-Orozco,Jorge Guerrero-Ixtlahuac,David Hernández-Barajas,Raymundo Hernández-Montes de Oca,Javier Kelly-García,Miguel Lázaro-León,Fernando Silva-Bravo,José Luis Téllez-Becerra,Eleazar Omar Macedo-Pérez,Gibert Maza-Ramos,José Luis Mayorga-Butrón,Bertha Beatriz Montaño-Velázquez,Karina Murillo-Medina,Salvador Narváez-Fernández,Francisco J Ochoa-Carrillo,Guillermo Olivares-Beltrán,Carlos Olivares-Torres,Mario Ponce de León-Castillo,Mario Alberto Ponce-Viveros,Jaime Ernesto Rubio-Gutiérrez,Julia Angelina Sáenz-Frías,Jorge Alberto Silva-Vivas,Patricio Santillán-Doherty,Juan José Soto-Ávila,Vinicio Toledo-Buenrostro,Benito Vargas-Abrego,Liliana Velasco-Hidalgo,Marta Margarita Zapata-Tarres,Gregorio Quintero-Beuló,Oscar Arrieta +60 more
TL;DR: The Guia de Practica Clinica de Guia (GPC) as discussed by the authors is a guia of the Sociedad Mexicana de Oncologia (Sociedad Mexico-Oncología), a group of physicians, especialistas, pacientes, cuidadores de pacients, and elaboradores de politicas pu-blicas involucrados involved in the manejo de paciente con cancer de pulmon.